WEST LAFAYETTE, IN, September 21, 2022 — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), is pleased to announce Matt Vaneman as the Company’s Vice President, Operational Excellence, effective September 6, 2022.
Greg Beattie, Inotiv’s Chief Operations Officer, Discovery and Safety Assessment (DSA), commented, “Operational Excellence means focusing on the critical factors that underlie success by optimizing our people, equipment and facilities. It’s the result of establishing systems and processes that lead to best-in-class performance by any measure, including quality, productivity, and the employee and client experience. Matt embodies this definition with a track record of success in leading organizations to achieve ambitious strategic and performance goals. He is team-oriented, approachable and collaborative. I couldn’t be more pleased to welcome him to the Inotiv team.”
Mr. Vaneman is an operations expert with over 25 years’ experience, most recently serving as Sr. VP, Operational Excellence, at Frontage Laboratories, where he provided extensive strategic insight in spearheading global operational excellence across Frontage’s 18 sites and business units. Prior to Frontage Laboratories, Mr. Vaneman led operational global process improvements, M&A activities, and employee development opportunities at Charles River Laboratories.
Mr. Vaneman concluded, “As a leader, I’m always looking for ways to create opportunities for others to succeed. I believe in mentoring individuals and teams to help them determine paths forward as a way to better the person, the team and the company.”
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company’s filings with the U.S. Securities and Exchange Commission.
|Company Contact||Investor Relations|
|Inotiv, Inc.||The Equity Group Inc.|
|Beth A. Taylor, Chief Financial Officer||Devin Sullivan|
|(765) 497-8381||(212) 836-9608|